Upcoming Post-Conference Perspectives: ASH 2021

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Now Viewing

EP: 1.Upcoming Post-Conference Perspectives: ASH 2021

EP: 2.The MASTER Trial: Frontline Dara-KRd in Newly Diagnosed Multiple Myeloma

EP: 3.Frontline Use of Daratumumab-Based Regimens in Transplant-Ineligible MM

EP: 4.Rescue Isatuximab in Transplant-Ineligible, Treatment Naïve NDMM

EP: 5.Multiple Myeloma: Current Approaches to Frontline Therapy

EP: 6.2-Year Followup Data From the GRIFFIN Trial in Transplant-Ineligible NDMM

EP: 7.Novel Therapy for Multiple Myeloma: Future Directions in Care

EP: 8.How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

Related Videos

Related Content

Advertisement

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).

April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.

April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.

March 25th 2025

Making Bispecific Therapies Work in Community Settings

Kyle Munz Ajai Chari, MD

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

March 21st 2025

Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM

Kyle Munz Ajai Chari, MD

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.

Related Content

Advertisement

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).

April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.

April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.

March 25th 2025

Making Bispecific Therapies Work in Community Settings

Kyle Munz Ajai Chari, MD

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

March 21st 2025

Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM

Kyle Munz Ajai Chari, MD

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.